Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2026-01-06 @ 6:33 PM
Study NCT ID:
NCT00686634
Status:
COMPLETED
Last Update Posted:
2014-11-26
First Post:
2008-05-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sitagliptin in Combination With Metformin and Sulfonylurea
Sponsor:
Charles Drew University of Medicine and Science
Organization:
Study Overview
Official Title:
Sitagliptin in Combination Oral Agent Therapy for Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in comparison to thiazolidinediones as the third-line oral agent, in patients with type 2 diabetes mellitus.
Detailed Description:
The aim of this protocol is to determine the non-inferiority of the effectiveness of sitagliptin compared to a control group of patients treated with thiazolidinediones as add-on therapy, in low-income ethnic minority type 2 diabetic patients who are failing to maintain adequate control with maximal doses of metformin and a sulfonylurea agent.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| U54RR014616 | NIH | None | https://reporter.nih.gov/quic… | View |